舒利迭治疗中、重度慢性阻塞性肺病疗效评价  

Evaluation on the clinical efficacy of Seretide in the treatment of moderate to severe chronic obstructive pulmonary disease

作　　者：颜正茂[1] 王昌惠[1] 张国良[1] 梅爱红[1] 傅佩芳[1] 

机构地区：[1]同济大学附属第十人民医院呼吸科,上海200072

出　　处：《上海医药》2010年第12期562-564,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:观察舒利迭(50/500μg)在慢性阻塞性肺病(COPD)缓解期中的疗效。方法:确诊的中、重度COPD患者40例,随机分为对照组和治疗组。对照组给予解痉平喘、祛痰等基础治疗;治疗组在此基础上给予舒利迭50/500μg,每次1吸,每日2次。分别对两组患者治疗前后的临床症状及肺功能指标进行观察对比,评价药物疗效。结果:治疗组患者治疗前后FEV1、FEV1/FVC×100%、FEV1%预计值差异具有统计学意义(P<0.05),而对照组治疗前后各指标差异无统计学意义。结论:在中、重度COPD患者中应用舒利迭能提高患者肺功能,明显改善症状,提高生活质量。Objective：To observe the clinical efficacy of Seretide（50/500 μg） on chronic obstructive pulmonary disease（COPD） in the remission period.Methods：Forty patients with moderate to severe COPD were diagnosed.They were randomly divided into two groups：the control group and the treatment group.The patients in the control group were given primary therapies to relieve airway spasm and asthma and eliminate phlegm.The patients in the treatment group were inhaled administered Seretide（50/500 μg per inhalation,b.i.d） on the basis of the primary treatment.The clinical symptoms and pulmonary functions of the two groups were observed and compared before and after therapy.The clinical efficacy of Seretide was evaluated.Results：The differences in FEV1,FEV1/FVC×100%,and FEV1% were significant in the treatment group before and after therapy（P 0.05）.But they were not significant in the control group before and after therapy.Conclusion：Seretide can elevate the pulmonary function,improve clinical symptoms,and increase the quality of life in the patients with moderate to severe COPD.

关 键 词：舒利迭 慢性阻塞性肺病 疗效观察 

分 类 号：R563.9[医药卫生—呼吸系统]